Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma

References

• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–3077.
   PubMed Web of Science ®Google Scholar
• Horwich A, Babjuk M, Bellmunt J, et al. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO guidelines committees. Ann Oncol. 2019;30(11):1697–1727.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016;14(1):1–20.
   PubMedGoogle Scholar
• Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–2438.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†. Eur Urol. 2020;77(2):223–250.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Watson D, Tourtellott M, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012;10(1):1–5.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Pal SK, Lin SW, et al. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States. Bladder Cancer. 2018;4(2):227–238.
   PubMed Web of Science ®Google Scholar
• Bamias A, Tzannis K, Harshman LC, RISC Investigators, et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC). Ann Oncol. 2018;29(2):361–369.
   PubMed Web of Science ®Google Scholar
• Fisher MD, Shenolikar R, Miller PJ, et al. Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008–2015. Clin Genitourin Cancer. 2018;16(6):e1171–e1179.
   PubMed Web of Science ®Google Scholar
• Small AC, Tsao CK, Moshier EL, et al. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer. 2012;118(23):5947–5954.
   PubMed Web of Science ®Google Scholar
• Dohn LH, Omland LH, Stormoen DR, et al. Status of metastatic bladder cancer treatment illustrated by a case. Semin Oncol Nurs. 2021;37(1):151113.
   PubMed Web of Science ®Google Scholar
• The Danish Bladder Cancer Group- Clinical guidelines (in Danish). Available from: http://www.skejby.net/DaBlaCa-web/DaBlaCaWEB.htm
   Google Scholar
• R Core Team. 2021. R: a language and environment for statistical computing. R foundation for statistical computing. Vienna, Austria. URL Available from: https://www.r-project.org/.
   Google Scholar
• Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591.
   PubMed Web of Science ®Google Scholar
• Cornet R, de Keizer N. Forty years of SNOMED: a literature review. BMC Med Inform Decis Mak. 2008;8(S1):S2.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e213.
   PubMed Web of Science ®Google Scholar
• Szabados B, Prendergast A, Jackson-Spence F, et al. Immune checkpoint inhibitors in front-line therapy for urothelial cancer. Eur Urol Oncol. Published Online. 2021; 82:212–222.
   Google Scholar
• Omland LH, Lindberg H, Carus A, et al. Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study. Eur Urol Open Sci. 2021;24:1–8.
   PubMedGoogle Scholar
• Neeman E, Gresham G, Ovasapians N, et al. Comparing physician and nurse eEastern cooperative oncology group performance status (ECOG‐PS) ratings as predictors of clinical outcomes in patients with cancer. Oncologist. 2019;24(12):e1460–e1466.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–1855.
   PubMed Web of Science ®Google Scholar
• Khochikar M. Rationale for an early detection program for bladder cancer. Indian J Urol. 2011;27(2):218–225.
   PubMedGoogle Scholar
• Rouanne M, Gaillard F, Meunier ME, et al. Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer. Sci Rep. 2020;10(1):16145.
   PubMed Web of Science ®Google Scholar
• Vejlgaard M, Maibom SL, Stroomberg HV, et al. Long-term renal function following radical cystectomy for bladder cancer. Urology. Published Online. 2021;160:147–153.
   PubMed Web of Science ®Google Scholar
• Campbell GA, Hu D, Okusa MD. Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis. 2014;21(1):64–71.
   PubMed Web of Science ®Google Scholar
• Konradsen AA, Lund CM, Vistisen KK, et al. The influence of socioeconomic position on adjuvant treatment of stage III Colon cancer: a systematic review and meta-analysis. Acta Oncol. 2020;59(11):1291–1299.
   PubMed Web of Science ®Google Scholar
• Eriksen KT, Petersen A, Poulsen AH, et al. Social inequality and incidence of and survival from cancers of the kidney and urinary bladder in a population-based study in Denmark, 1994–2003. Eur J Cancer. 2008;44(14):2030–2042.
   PubMed Web of Science ®Google Scholar
• Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–1492.
   PubMed Web of Science ®Google Scholar
• Sargent D. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist. 2010;15(S1):19–23.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–2347.
   PubMed Web of Science ®Google Scholar